EUVIMEDEUVIMED entdecken
Crossref

Nonclinical Validation of the NexPTM Half-Life Extension Platform Using Human Growth Hormone as a Model Therapeutic Protein

Jaehyeong Ko, Changkwon Song, Kibum Park, Jeong Soo Cho, Jinhee Lee, Minsoo Byun, Yi Jin Song, Ji-sun Kim, Ji Eun Hong, Sang Hee Lee, Sun-Ah You, Sang Mee Lee und 4 weitere

Molecular Pharmaceutics · 17.11.2026

DOI: 10.1021/acs.molpharmaceut.6c01038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 17.11.2026. Verfasst von Jaehyeong Ko und 15 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Korea Evaluation Institute of Industrial Technology.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NexP™ is a proprietary carrier platform engineered from human alpha-1 antitrypsin (A1AT) to extend the systemic exposure of therapeutic proteins while retaining biological activity. The NexP™ scaffold incorporates an additional N-linked glycosylation site and a mutation in the reactive center loop designed to reduce its intrinsic protease inhibitory activity. Human growth hormone (hGH) was selected as a model therapeutic protein to evaluate the pharmacological performance, safety profile, and developability of the NexP™ platform. ALT-P1, a long-acting hGH candidate, containing NexP™ at its C-terminus of hGH, was produced in mammalian cells and purified by a series of column chromatography steps. The purified protein was characterized Human growth hormone (hGH) was selected as a model therapeutic protein to evaluate the pharmacological properties, nonclinical safety, and developability of this platform. ALT-P1, an hGH fusion protein containing NexP™ at its C-terminus, was produced in mammalian cells and purified using chromatographic methods. ALT-P1 was characterized by physicochemical analyses, including SDS-PAGE, isoelectric focusing, size-exclusion chromatography, N-linked glycan profiling, and circular dichroism (CD) spectroscopy. Binding affinity for the human growth hormone receptor and in vitro activity were further assessed by receptor-binding, MTS-based cell proliferation and luciferase reporter assays. Pharmacokinetic, pharmacodynamic, and toxicological profiles were evaluated in Sprague-Dawley rats and cynomolgus monkeys. Systemic exposure to ALT-P1 increased with increasing subcutaneous doses in rats, and pharmacokinetic studies demonstrated sustained systemic exposure in both species. ALT-P1 increased serum insulin-like growth factor I (IGF-1) levels in cynomolgus monkeys and promoted body weight gain and tibial growth in hypophysectomized rats. In a 26 week repeated-dose toxicity study in cynomolgus monkeys, ALT-P1 was generally well tolerated, with a no-observed-adverse-effect level (NOAEL) of 20 mg/kg, the highest dose tested. A GMP-manufactured clinical batch maintained its quality attributes and biological potency during long-term storage. Collectively, these findings support the further development of ALT-P1 as a long-acting hGH candidate and suggest the potential applicability of NexP™ as a half-life-extension platform for other biologic therapeutics.

Förderung

  • Korea Evaluation Institute of Industrial Technology

Zitieren

APA

Ko, J., Song, C., Park, K., Cho, J. S., Lee, J., Byun, M., Song, Y. J., Kim, J., Hong, J. E., Lee, S. H., You, S., Lee, S. M., Kim, K., Chun, T., Chung, H., & Park, S. J. (2026). Nonclinical Validation of the NexPTM Half-Life Extension Platform Using Human Growth Hormone as a Model Therapeutic Protein. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c01038

Vancouver

Ko J, Song C, Park K, Cho JS, Lee J, Byun M, et al. Nonclinical Validation of the NexPTM Half-Life Extension Platform Using Human Growth Hormone as a Model Therapeutic Protein. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c01038

BibTeX
@article{Ko2026,
  author = {Ko, Jaehyeong and Song, Changkwon and Park, Kibum and Cho, Jeong Soo and Lee, Jinhee and Byun, Minsoo and Song, Yi Jin and Kim, Ji-sun and Hong, Ji Eun and Lee, Sang Hee and You, Sun-Ah and Lee, Sang Mee and Kim, Kyuwan and Chun, Tae-Yon and Chung, Hye-Shin and Park, Soon Jae},
  title = {Nonclinical Validation of the NexPTM Half-Life Extension Platform Using Human Growth Hormone as a Model Therapeutic Protein},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.6c01038}
}
Kostenlos starten →